Senseonics (NYSE:SENS) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Senseonics (NYSE:SENS) in a research report issued to clients and investors on Wednesday. The brokerage set a “sell” rating on the stock.

Senseonics Stock Performance

Shares of NYSE:SENS opened at $0.39 on Wednesday. The company has a quick ratio of 3.70, a current ratio of 3.96 and a debt-to-equity ratio of 1.79. Senseonics has a 52-week low of $0.37 and a 52-week high of $1.05. The stock has a market cap of $207.63 million, a price-to-earnings ratio of -2.79 and a beta of 0.82. The business has a 50-day moving average price of $0.43 and a 200-day moving average price of $0.52.

Senseonics (NYSE:SENS) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.03). The company had revenue of $5.05 million during the quarter, compared to analyst estimates of $4.76 million. Senseonics had a negative net margin of 346.38% and a negative return on equity of 202.32%. Equities analysts predict that Senseonics will post -0.12 EPS for the current year.

Institutional Investors Weigh In On Senseonics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SENS. RPO LLC acquired a new position in shares of Senseonics in the 4th quarter valued at about $37,000. State Board of Administration of Florida Retirement System acquired a new stake in Senseonics during the first quarter worth about $91,000. Virtu Financial LLC purchased a new position in Senseonics during the first quarter valued at approximately $162,000. Price T Rowe Associates Inc. MD lifted its holdings in Senseonics by 16.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after acquiring an additional 51,000 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Senseonics by 30.2% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock worth $483,000 after purchasing an additional 211,128 shares in the last quarter. 12.36% of the stock is owned by institutional investors and hedge funds.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.